Document:

EX-10.10

 Exhibit 10.10 

CONFIDENTIAL 
 Confidential portions of this
document have been omitted and have been filed separately with the Securities and Exchange Commission pursuant to an application for confidential treatment requested under Rule 406 of the Securities Act of 1933, as amended. [**] indicates omitted
material that is the subject of the confidential treatment request filed separately with the Commission. 
 RESEARCH COLLABORATION
AGREEMENT 
 This Research Collaboration Agreement (“Agreement”) is made effective this 15th day of December, 2014 (“Effective Date”), by and between XBiotech USA, Inc. (“XBiotech”), a Delaware corporation whose principal place of business is located at
8201 East Riverside Drive, Building 4, Suite 100, Austin, TX 78744, and South Texas Blood & Tissue Center, a Texas 501(c)(3) non-profit corporation (“STBTC”), whose principal place of business is
located at 6211 IH 10 West, San Antonio, Texas 78201. Individually each may also be referred to herein as a “Party” and collectively referred to as the “Parties”. 

RECITALS 
 WHEREAS,
XBiotech has developed certain proprietary technology and know-how for blood sample screening, identification of naturally occurring antibodies in human blood, B-cell and RNA isolation, mammalian cell transfection and overall development of True
HumanTM therapeutic monoclonal antibodies, (collectively, the “XBiotech Technology”). 
 WHEREAS, STBTC is engaged in
collecting human blood from adult donors, processing and separation of collected blood into components, and providing human blood, plasma, platelets and other blood components to hospitals and medical facilities. 

WHEREAS, XBiotech must have access to both standard blood donor samples (for screening) and fresh, live cells from select donors for isolation
of genetic information to produce therapeutic antibodies. 
 WHEREAS, STBTC has determined providing such access to XBiotech is consistent
with the mission of STBTC. 
 WHEREAS, the parties acknowledge the Mutual Non-Disclosure Agreement executed by and between the Parties dated
effective October 30, 2014. 
 WHEREAS, XBiotech and STBTC would like to collaborate on the terms and conditions set forth herein in
the research project described more fully in Exhibit A to identify and develop therapeutic monoclonal antibodies (the “Project”). 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

1 

 CONFIDENTIAL 
  

WHEREAS, all entities controlled by or under common control with a Party shall be defined as that Party’s “Affiliates”. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the Parties agree as follows: 

I. Research Project Description. The Parties will cooperate in accordance with the terms and conditions of this Agreement to achieve the goals
of the Project. 
 II. Obligations To Be Undertaken by the Parties. 

A. STBTC will use commercially reasonable best efforts to perform the following activities: 

1. Review the protocols proposed by XBiotech for purposes of completing the Project and recommend modifications as appropriate. 

2. Provide XBiotech blood samples from at least one recent survivor of an Ebola infection with high likelihood of having high levels of active
anti-ebolavirus antibodies and B-Cells with RNA coding for same. 
 3. Obtain appropriate and sufficient patient informed consent from blood
donors who donate blood for the Project. 
 4. Provide to XBiotech patient blood samples for XBiotech testing,
B-Cell and RNA isolation per protocol. 
 5. Provide assay services per Institutional Review
Board-approved protocol for the Project that are within the scope of STBTC’s current in-house testing capabilities. If additional assay or other sample testing services are requested by XBiotech, STBTC will facilitate identification of
third-party or affiliate capabilities and transfer of sample(s) to the appropriate service provider for testing at XBiotech’s cost, with prior written approval by XBiotech. 

6. Report the results of all such tests solely to XBiotech and provide such written documentation of the results as shall be reasonably
requested. 
 7. Maintain all records required for business and regulatory purposes, e.g., design control files, and provide XBiotech with
reasonable access to such files for compliance with law. 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

2 

 CONFIDENTIAL 
  

B. XBiotech will use commercially reasonable best efforts to perform the following activities: 

1. Provide financial compensation to STBTC for plasma samples ($10 per sample) and units of whole blood ($375 per unit) collected at STBTC
facilities or with use of STBTC equipment. XBiotech will also reimburse reasonable costs for a donor’s time and travel if applicable. 

2. Provide STBTC scientific protocols for conducting STBTC’s blood collection and analysis efforts in the Project. 

3. Participate in the review and discussion of the results and findings of STBTC’s testing. 

4. Prepare the combination informed consent document and written authorization to comply with applicable law to authorize obtaining, sharing
and using information from study participants, and submit the same to an a suitable Institutional Review Board after receiving and addressing any questions or comments from STBTC. 

5. Prepare and finalize the blood collection protocols and submit to a suitable Institutional Review Board after receiving and addressing any
questions or comments from STBTC. 
 6. Be solely responsible for any product, plasma, blood or cell sample provided by STBTC to XBiotech,
including responsibility for the shipping, storage, distribution and use of any product, plasma, blood or cell sample. 
 III. Intellectual
Property. 
 A. “Intellectual Property” means inventions, discoveries, tangible rights in biological materials, patents
and patent applications, trade secrets, copyrights, trademarks, and proprietary know-how. 
 B. “Existing Technology” means all
inventions, know-how, technologies, and techniques, including any Intellectual Property therein, owned or controlled by XBiotech or STBTC respectively, prior to the Effective Date. Existing Technology of a Party shall be and remain the sole property
of such Party. Subject to the termination provisions of Section VIII, STBTC shall have the right to use XBiotech’s Existing Technology solely for accomplishing its 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

3 

 CONFIDENTIAL 
  

obligations in the Project, and XBiotech hereby grants to STBTC a limited, revocable, non-transferable, non-exclusive, non-sublicenseable, royalty-free license under XBiotech’s Existing
Technology, to perform its obligations under this Agreement in the United States, solely for the Term hereof. Notwithstanding anything herein to the contrary, XBiotech shall have the right to use any of STBTC’s rights in tangible biological
materials for the purpose of commercially developing any Jointly Developed Technology in accordance with Section III.D of this Agreement. 

C. “Jointly Developed Technology” means antibodies and antibody-encoding nucleic acids derived from blood or cell samples isolated
from one or more blood samples which STBTC makes available to XBiotech under this Agreement, and after the Effective Date. XBiotech hereby is, and shall be, vested with the sole right and authority to register, file and prosecute patent applications
(including the right to withdraw, limit or abandon any claim at any time) and/or take any other steps necessary to protect any Jointly Developed Technology as XBiotech shall see fit in its sole discretion and at its sole expense. 

D. All Jointly Developed Technology shall: 
  

	 	1.	be owned solely by XBiotech, and STBTC assigns to XBiotech all title and interest in any and all Jointly Developed Technology including any intellectual property rights therein. In consideration of this assignment,
XBiotech shall to pay STBTC a royalty of: 

  

	 	•	 	[**]% on the Global Net Sales of an Ebola Virus Therapeutic Antibody if such antibody was derived from blood or cell samples provided by STBTC; 

 

	 	•	 	[**]% on the Global Net Sales for each therapeutic antibody product other than an Ebola Virus Therapeutic if such antibody was derived from blood or cell samples provided by STBTC after the Effective Date of this
Agreement; 

 “Global Net Sales” for purposes hereof shall mean the total amount received by XBiotech from the sale
of antibody products based on Jointly 

  
 Research Collaboration Agreement
XBiotech USA / South Texas Blood & Tissue Center 
  

	 	[**]	Confidential Treatment requested. Omitted portions have been filed separately with the Securities and Exchange Commission. 

  

4 

 CONFIDENTIAL 
  

Developed Technology for any consideration, less allowances; trade, quantity or cash discounts; credits or allowances for returns or rejections; duties, tariffs, excise taxes or other charges
levied by any governmental agency; and/or any legal charge that effectively reduces the per-unit sales price. For clarity, royalties payable to STBTC on Global Net Sales shall be payable to STBTC whether said sales are made by XBiotech or another
third party. 
 E. The Parties agree to keep and maintain adequate, current, accurate, and authentic written records of all Jointly
Developed Technology during the Term of this agreement and for a period of three (3) years thereafter, unless a longer period is required by federal law applicable to XBiotech, and to deliver such records upon written request to the other
Party. 
 IV. Representations and Warranties.  

A. STBTC represents and warrants: 

1. All action on the part of STBTC necessary for the authorization, execution and delivery of this Agreement has been completed. 

2. The execution and delivery of this Agreement and STBTC’s performance of its obligations hereunder does not conflict with any other
agreement to which STBTC is a party. 
 3. STBTC is participating in the Project strictly for research purposes and will not use XBiotech
Technology or STBTC biomaterials with XBiotech Technology in or for any human patient while performing the Project. 
 4. STBTC has, or will
prior to the commencement of work on the Project, require its principal investigator(s), each individual employee assigned by STBTC to perform under this Agreement, and any and all independent contractors engaged to work on the Project (a) to
fulfill the responsibilities encompassed within this Agreement and (b) to enter into a written agreement assigning all of their rights to Jointly Developed Technology and any intellectual property therein to XBiotech in a manner consistent with
STBTC’s agreement to assign STBTC’s rights to XBiotech as set forth above. 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

5 

 CONFIDENTIAL 
  

B. XBiotech represents and warrants: 

1. All action on the part of XBiotech, its directors, and officers necessary for the authorization, execution and delivery of this Agreement
has been completed. 
 2. The execution and delivery of this Agreement and XBiotech’s performance of its obligations hereunder does not
conflict with any other agreement to which XBiotech is a party. 
 3. XBiotech will comply with all applicable human research subject
protections required by applicable law and regulations in performance of this Agreement and the commercial development of all Jointly Developed Technology. 

C. XBIOTECH EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, RELATIVE TO ANY XBIOTECH TECHNOLOGY OR ANY OTHER PRODUCT OR
TECHNOLOGY UNDER THIS AGREEMENT, INCLUDING BY WAY OF EXAMPLE AND NOT BY LIMITATION, ANY WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONFORMANCE TO SPECIFICATION, OR COMPLIANCE WITH ANY RULE OR REGULATION OF ANY
AUTHORITY. NOTWITHSTANDING THE FOREGOING, XBIOTECH HAS SOLE RESPONSIBILITY FOR ANY PRODUCT, PLASMA, BLOOD OR CELL SAMPLE PROVIDED BY STBTC, INCLUDING WITHOUT LIMITATION RESPONSIBILITY FOR THE SHIPPING, STORAGE, DISTRIBUTION AND USE OF ANY PRODUCT,
PLASMA, BLOOD OR CELL SAMPLE. 
 D. STBTC EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, RELATIVE TO ANY STBTC TECHNOLOGY
OR ANY OTHER PRODUCT OR TECHNOLOGY UNDER THIS AGREEMENT, INCLUDING BY WAY OF EXAMPLE AND NOT BY LIMITATION, ANY WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONFORMANCE TO SPECIFICATION, OR COMPLIANCE WITH ANY
RULE OR REGULATION OF ANY 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

6 

 CONFIDENTIAL 
  

AUTHORITY. STBTC EXPRESSLY DOES NOT WARRANT ANY PRODUCT, PLASMA, BLOOD OR CELL SAMPLE PROVIDED TO XBIOTECH UNDER THIS AGREEMENT NOR DOES STBTC ASSURE, REPRESENT OR WARRANT TO XBIOTECH THAT ANY
SUCH PRODUCT, PLASMA, BLOOD OR CELL SAMPLE WILL YIELD ANY ANTIBODIES FOR XBIOTECH’S PURPOSES. 
 V. Compensation and Expense
Reimbursement 
 A. In consideration of the services provided to XBiotech by STBTC hereunder, XBiotech shall pay STBTC ten dollars
($10) per plasma sample and three hundred seventy five dollars ($375) for each single unit of whole blood delivered to XBiotech. Courier fees shall be included in the foregoing amount. XBiotech shall pay STBTC for such costs within thirty
(30) days of receipt of an invoice for same. Furthermore, XBiotech agrees to pay interest on past due amounts at 18 percent per annum from the date the invoice becomes past due, until payment has been made. XBiotech shall not be responsible for
any additional payment to STBTC including for reimbursement of any costs arising out of inspections or audits by officials of competent authorities. Notwithstanding such consideration as partial reimbursement for STBTC’s services, the Parties
agree said consideration does not imply a work for hire relationship. 
 VI. Reports. 

A. The Parties agree to keep and maintain adequate, current, accurate, and authentic written records of the results of their respective
contribution in fulfillment of the Project, as described in Exhibit A, in sufficient detail and in accordance with good scientific research practices. Each Party agrees to promptly provide to the other Party written reports of the Project and the
results obtained, in a timely manner. 
 VII. Term, Termination and Survival. 

A. The term of this Agreement will begin on the Effective Date and will continue until the earlier of (i) final completion of the Project
to be confirmed by written notice from the Party certifying that Party’s completion of the Project to the other Party, subject to the Party receiving the notice verifying to its reasonable satisfaction that Project deliverables have been
received, or (ii) termination as provided in VIII.B (“Term”). 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

7 

 CONFIDENTIAL 
  

B. Either Party may terminate this agreement prior to the completion of the Project, by giving at least thirty (30) days prior written
notice to the other Party. 
 C. Upon any termination, all rights and duties of the Parties toward each other will cease except that
Section III (Intellectual Property), Section VII (Reports), Section VIII (Term, Termination, and Survival), Section IX (Confidential Information), Section X (Indemnification and Insurance) and Section XI (Miscellaneous)
will survive termination. 
 D. In the event that either Party commits a material breach or default of any of the terms or conditions of
this Agreement, and the breaching Party fails to remedy that default or breach within thirty (30) days after receipt of written notice of such breach from the non-breaching Party, the Party giving notice may, at its option and in addition to
any other remedies it may have in law or in equity, terminate this Agreement by sending written notice of termination to stop any work in progress as soon as it is practicable to do so. 

VIII. Confidential Information. 

A. “Confidential Information” means any non-public information of the disclosing Party that relates to the actual or anticipated
business and/or products, research or development of such Party, its Affiliates or subsidiaries, or to that Party’s Affiliates’ or subsidiaries’ Intellectual Property, technical data, trade secrets, or know-how, including, but not
limited to, research, product plans, or other information regarding such Party, its Affiliates’ or subsidiaries’ products or services and markets, customer lists and customers, software, developments, inventions, processes, formulas,
technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business information, information relating to the employees, clients, suppliers and vendors of the Party or its Affiliates, any analysis,
compilations, notes, data studies or other documents prepared by a Party or any of its Representatives containing any such furnished information or based, in whole or in part, upon any such furnished information, whether or not disclosed in writing
or orally. Confidential Information need not be labeled or stamped as confidential. For purposes of this Agreement, (a) an “Affiliate” of a party shall include any entity that is controlled by, under common control of, or controls
such party, and (b) “Representatives” means the attorneys, accountants, financial advisors, consultants and such Party’s directors, officers and employees of the Party or the Party’s Affiliates. 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

8 

 CONFIDENTIAL 
  

Notwithstanding the foregoing, Confidential Information shall not include any such information which the receiving Party can establish
(i) was publicly known or made generally available prior to the time of disclosure to the receiving Party; (ii) becomes publicly known or made generally available after disclosure to such Party through no wrongful action or inaction of the
receiving Party or wrongful action or breach of confidentiality covenant of another person; or (iii) is in the rightful possession of the receiving Party, without confidentiality obligations, at the time of disclosure as shown by the receiving
Party’s then-contemporaneous written records. 
 B. Non-use and Nondisclosure. Except with the prior written consent of
the disclosing Party, during and after the Term of this Agreement, the receiving Party will hold in the strictest confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of the Confidential Information, and
neither Party will (i) use Confidential Information for any purpose whatsoever other than as necessary for the performance of the Project, nor (ii) disclose Confidential Information to any third party without the prior written consent of
an authorized representative of the disclosing Party, except that the receiving Party may disclose Confidential Information to its Representatives on a need-to-know basis for the purposes of assisting a party to perform the Project. The receiving
Party may also disclose Confidential Information to the extent compelled by applicable law, or required to comply with a governmental regulation, or requested by a governmental authority or an accrediting organization or association; provided
however, prior to such disclosure, such Party shall provide prior written notice to the disclosing Party and the Parties shall cooperate to decide on the process, terms and conditions to disclose Confidential Information responsive to the request by
a governmental authority or accrediting organization. If a Party receives a subpoena, or other order seeking disclosure of Confidential Information, the Parties shall cooperate to decide on the process, terms and conditions to disclose Confidential
Information responsive to the subpoena or order, which may include seeking a protective order or such similar confidential protection as may be available under applicable law. The Parties agree that no ownership of Confidential Information is
conveyed by the disclosing Party to the receiving Party. Each Party agrees that the Parties obligations under this subsection shall continue after the termination of this Agreement. In the 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

9 

 CONFIDENTIAL 
  

event of a conflict between this Section IX and a nondisclosure agreement signed by the Parties, this Section IX shall control. Notwithstanding anything herein or in the Mutual Non-Disclosure
Agreement executed by and between the Parties dated effective October 30, 2014, XBiotech shall be free to use and disclose any of STBTC’s confidential information developed in the Project as required to commercially develop any Jointly
Developed Technology in accordance with Section III.D of this Agreement. 
 IX. Indemnification and Insurance. 

A. Subject to the limitations of Section C of this Article X, each Party shall defend, indemnify and hold harmless the other Party and its
respective parent and subsidiary entities, Affiliates, directors, officers, members, employees and agents from and against any and all losses, claims, damages, demands, suits, liabilities, and expenses, including reasonable attorneys’ fees and
costs incurred in connection therewith, arising as a result of (a) the indemnifying Party’s material breach of the representations or warranties set forth in this Agreement, (b) the negligence, gross negligence or willful misconduct
of the indemnifying Party in performing its duties through employees, agents or contractors under this Agreement, or (c) any governmental investigation or proceeding initiated as a result of the indemnifying Party’s breach, misconduct or
performance under this Agreement. 
 B. Each Party shall maintain in force at its sole cost and expense, with reputable insurance companies,
insurance of types and amounts reasonably sufficient to protect against liability hereunder including product liability, professional liability and commercial general liability of at least $1 million per occurrence and $5 million in the aggregate;
and at least statutory limits for workers compensation insurance (or program of self-insurance if permitted by applicable state law). Each Party shall provide the other party with a certificate(s) of insurance upon written request from the other
Party 
 C. UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER FOR INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL
DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS UNDER ANY CIRCUMSTANCE, INCLUDING BREACH OR FAILURE TO PERFORM A PARTY’S DUTY UNDER THIS AGREEMENT OR LOSS OF DATA. 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

10 

 CONFIDENTIAL 
  

X. Miscellaneous. 
 A.
Governing Law. The construction, interpretation, and performance of the obligations of this Agreement will be governed by the laws of the State of Texas without regard to conflict of law provisions. Any disputes under this Agreement
shall be subject to the exclusive jurisdiction and venue of Texas state courts and the Federal courts located in Bexar County Texas, and the Parties hereby irrevocably consent to the personal jurisdiction and venue of these courts. 

B. Notices. All notices required or permitted under this Agreement shall be delivered in person, by confirmed facsimile,
by confirmed email or by certified mail, return receipt requested, postage prepaid, to the Party receiving notice in care of the Party’s authorized representative identified as the signatory to this Agreement at the Party’s address stated
in this Agreement, or to such other address as the Party to receive notice may specify to the other Party by written notice pursuant to this paragraph. Notices shall be effective on personal delivery, confirmed receipt of the email or facsimile, or
on the third business day following the date of mailing.  
 C. Assignment and Relationship of the Parties.
Neither this Agreement, nor the rights or obligations of any Party hereto, may be assigned without the prior written consent of the other Party. Notwithstanding the foregoing, STBTC may assign this Agreement without XBiotech’s consent to an
Affiliate of STBTC. This Agreement will inure to the benefit of, and be binding upon each of the heirs and permitted assigns and successors of the Parties. Each Party will perform under this Agreement solely as an independent contractor. Under no
circumstances will any of a Party’s personnel be considered employees or agents of the other Party. Nothing in this Agreement grants either Party the right or authority to make commitments of any kind for the other, implied or otherwise,
without the other Party’s prior written approval. This Agreement does not constitute or create, in any manner, a joint venture, partnership, or formal business organization of any kind. 

D. Entire Agreement. This Agreement, including its Exhibits, constitutes the entire agreement between the Parties and
supersedes all prior agreements and representations between the Parties hereto unless expressly stated otherwise in this Agreement. This Agreement may be  

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

11 

 CONFIDENTIAL 
  

amended or modified only in writing and duly signed by the Parties. If any provision of this Agreement shall be found by a court to be void, invalid or unenforceable, the same shall be reformed
to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement. 

E. Equitable Relief. The Parties acknowledge that their remedies at law for any breach or threatened breach of this Agreement
may be inadequate. Therefore, a Party shall be entitled to seek injunctive and other equitable relief restraining a Party from violating this Agreement, in addition to any other remedies that may be available to it under the law. 

[signature page follows] 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

12 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date. 

 

																	
	XBiotech				STBTC
					
	By:		     /s/ John Simard
				By:		     /s/ Linda Myers

					
			Name:		     John Simard
				Linda Myers, CEO
							
			Title:		     CEO
								
					
	Date:		     January 9, 2015
				Date:		     January 9, 2015

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

13 

 CONFIDENTIAL 
  

Exhibit A 
  

	I.	Protocol: Analysis of Whole Blood from Healthy Individuals to Discover Various Antibodies per Protocol 2010-PT016; VER: 1.8 of October 04, 2011 or as reasonably amended with mutual prior written agreement by the
Parties. 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

14 

 CONFIDENTIAL 
  

II. Protocol: 2014-PT028 Analysis of Whole Blood to Discover Antibodies to Ebola Virus From Individuals That Have Recovered From Infection (WIRB® Protocol #20142316) 

  
  

Research Collaboration Agreement XBiotech USA / South Texas Blood & Tissue Center 
  

15 

			
	Protocol No. 2014-PT028; VER: 1.0		1

  

			
	STUDY TITLE:		Analysis of Whole Blood to Discover Antibodies to Ebola Virus (EBOV) From Individuals That Have Recovered From Infection
		
	PROTOCOL NUMBER:		2014-PT028
		
	PROTOCOL VERSION / DATE:		VER 1.0/ 11 November 2014
		
	SPONSOR/INVESTIGATOR:		XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2900
		
			Michael Stecher, M.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2998
		
	STUDY SITE:		XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2900

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		2

  

 TABLE OF CONTENTS 

 

									
	 PROTOCOL SYNOPSIS
		 	3	  
			
	 1
		 BACKGROUND
		 	5	  
			
	 2
		 ELIGIBILITY CRITERIA
		 	5	  
			
	 3
		 INFORMED CONSENT
		 	5	  
			
	 4
		 DONOR SCREENING
		 	6	  
			
	 5
		 SAMPLE COLLECTION
		 	6	  
			
	 6
		 SAMPLE PROCESSING AND STORAGE
		 	6	  
				
			 6.1
		DURATION OF SAMPLE STORAGE		 	6	  
			 6.2
		VIAL LABELING		 	7	  
			 6.3
		SAMPLE PREPARATION		 	7	  
			
	 7
		 DONOR PRIVACY AND CONFIDENTIALITY
		 	7	  
				
			 7.1
		RECORD AND SAMPLE HANDLING		 	7	  
			 7.2
		ACCESS TO SAMPLES AND DONOR INFORMATION		 	8	  
			
	 8
		 USE OF BLOOD SAMPLES
		 	8	  
				
			 8.1
		RESTRICTIONS ON SAMPLE USAGE AT THE INVESTIGATIVE SITE		 	8	  

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		3

  

 PROTOCOL SYNOPSIS 

 

					
	Study Title		Analysis of Whole Blood to Discover Antibodies to Ebola Virus From Individuals That Have Recovered From Infection
		
	Sponsor		XBiotech USA, Inc.
		
	Investigator/Study Center:		Michael Stecher, M.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2998
		
	Objectives		Primary Outcome Measures:
			
			        •    		To identify antibodies against Ebola virus surface proteins.
		
			Secondary Objectives:
			
			        •		To make B-cell cDNA libraries in order to isolate antibody sequences.
		
	Study Rationale		Individuals that have been infected with Ebola virus and have successfully recovered may have antibodies against the virus. These antibodies could be used to develop an antiviral monoclonal antibody to treat infected
individuals.

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		4

  

							
		
	Trial Design		This is a single center study. The study will be conducted at XBiotech USA, using samples provided by volunteers who have recovered from Ebola virus infection, and are currently non-contagious. Study participants must be
willing to voluntarily consent to having their blood drawn for research purposes.
		
			Prior to donation, volunteers will be required to sign an IRB-approved consent, and will be asked to complete an additional health questionnaire provided by XBiotech. If the participant meets inclusion and exclusion
criteria, one unit (approximately 450 ml) of whole blood will be collected at South Texas Blood and Tissue Center (STBTC).

  

							
	Selection Criteria for screening		Inclusion Criteria:
			
			 1.    
		Male or female age > 18 years
			
			 2.
		Recovered from infection with Ebola virus and meeting the following criteria per WHO guidelines1:
				
					 a.    
		28 days after their date of discharge
				
					 b.
		Clinically asymptomatic
				
					 c.
		Twice tested negative for EBOV RNA by PCR (tests should be separated by at least 48 hours)
			
			 3.
		Signed and dated institutional review board (IRB)- approved informed consent before any study specific procedures are performed
		
			Exclusion Criteria:
			
			 1.
		History of bleeding disorders
			
			 2.
		Immunocompromised donors, including participants known to be infected with immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
			
			 3.
		Hematocrit <38% or platelet count <140 k/ul
		
	Approximate Number of Participants		Up to 20
		
	Analysis Methods		B-cells will be sorted and mRNA isolated from them will be used to prepare cDNA libraries.

  

	1 	World Health Organization. “Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks”. Version
1.0, September 2014. http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/ 

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		5

  

	1	Background 

 Individuals that have been infected with Ebola virus and have successfully recovered may
have antibodies against the virus. These antibodies could be used to develop an antiviral monoclonal antibody to treat infected individuals. 
  

	2	Eligibility Criteria 

 Inclusion Criteria: 

 

	 	1.	Male or female age > 18 years 

  

	 	2.	Recovered from infection with Ebola virus and meeting the following criteria per WHO guidelines: 

  

	 	a.	28 days after their date of discharge 

  

	 	b.	Clinically asymptomatic 

  

	 	c.	Twice tested negative for EBOV RNA by PCR (tests should be separated by at least 48 hours) 

  

	 	3.	Signed and dated institutional review board (IRB)- approved informed consent before any study specific procedures are performed 

Exclusion Criteria: 
  

	 	1.	History of bleeding disorders 

  

	 	2.	Immunocompromised donors, including participants known to be infected with immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) 

 

	 	3.	Hematocrit <38% or platelet count <140 k/ul 

  

	3	Informed Consent 

 A signed and dated IRB approved informed consent form will be obtained from each
participant in accordance with HHS regulations noted in 45 CFR 46.116 prior to drawing the blood. Verbal explanation of the research study including study specific procedures and potential risks will be described in detail by the Investigator or
designee. Study participants will have every opportunity to ask questions regarding his or her participation in the research study as detailed in the informed consent form. All questions and/or concerns will be addressed by the Investigator, or
designee, to the satisfaction of the study participant. The original signed consent form will be maintained by the Sub-Investigator in a secure file at STBTC. A copy of the original signed consent form will be given to the study participant. 

The Investigator/Sponsor will ensure that each study participant’s anonymity will be maintained in accordance with applicable laws. On study specific
source documents submitted to the Investigator/Sponsor by STBTC, study participants will be identified by the Study Unit Identifier (STU) provided by South Texas Blood and Tissue Center. 

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		6

  

	4	Donor Screening 

 Potential donors will be contacted by their treating physician. Travel to STBTC will be
arranged by XBiotech. Potential donors will undergo a basic history and examination. EBOV infection and convalescence will be confirmed both through patient history, and review of hospital discharge laboratory results. 

Data Collection: 
  

							
	Date of Collection				STU		
				
	Age				Gender		
				
	Date of Hospital Discharge				Weight		
				
	Temperature				Pulse		
				
	Blood Pressure				Hemoglobin and Platelet Count		
				
	EBOV RNA Result #1				Date		
				
	EBOV RNA Result #2				Date		
				
	Volume Collected				Type of anticoagulant		
				
	Start time				Stop time		
				
	Donor Reaction		Yes/No		Type of Reaction		
				
	Discharge Time				Discharge Pulse and Blood Pressure		

 This data collection form will be maintained in a secure file at STBTC along with de-identified copies of lab reports and/or
hospital records. External reports will be re-labeled with the participants Study Unit Identifier (STU). 
  

	5	Sample Collection 

 Blood samples will be collected from study participants via venipuncture at South
Texas Blood and Tissue Center in San Antonio, Texas. 
  

	6	Sample Processing and Storage 

 XBiotech personnel will receive the unit of whole blood for processing.
B-cells will be isolated and sorted, and mRNA isolated from them will be used to prepare cDNA libraries. 
  

	6.1	Duration of Sample Storage 

 Blood samples retained at XBiotech may be stored indefinitely. 

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		7

  

	6.2	Vial Labeling 

 Each sample will be labeled with a unique identifier, the “Study Unit
Identifier” (STU). Scientists at XBiotech will only have access to the STU, and not to any other donor identifiers, in order to ensure a higher level of participant confidentiality. STBTC phlebotomists will label each sample according to their
standard operating procedures. Any samples that have been separated into new containers or vials by scientists at XBiotech for storage or testing will also be labeled using the STU. 

 

	6.3	Sample Preparation 

 In order to determine if a patient is eligible to donate a unit of
blood, 4 vials of blood will be drawn according to STBTC SOPs. Blood counts and infectious disease screening tests will be performed on these samples. If eligible, approximately 450 milliliters of blood will be collected from study participants in a
CP2D (Citrate Phosphate Double Dextrose) bag at STBTC according to their SOPs. Peripheral blood mononuclear cells (PBMCs) from this sample will be isolated by XBiotech scientists, and RNA will be extracted. At this point, the sample can be flash
frozen and stored at -80° Celsius for future testing. The plasma will be stored at -80°C freezer for further testing as well. 
 If necessary to
isolate additional PBMCs, donors may be asked to donate a second unit of whole blood. If a second blood draw is requested, this should be scheduled at least 56 days after the initial unit of blood is drawn. 

 

	7	Donor Privacy and Confidentiality 

 The Investigator/Sponsor will ensure that each study
participant’s anonymity will be maintained in accordance with applicable laws. On study specific source documents submitted to the Investigator/Sponsor by STBTC, study participants should not be identified by their full name rather by the
specific unique identification number used by South Texas Blood and Tissue Center. Only XBiotech personnel authorized by the Principal Investigator will have direct access to the blood storage facilities and samples. 

 

	7.1	Record and Sample Handling 

 Blood samples arriving at XBiotech will be received and processed
only by XBiotech personnel designated by the Principal Investigator. Samples received, stored, and tested by XBiotech employees will only be labeled with a Study Unit Identifier (STU). This number will be generated according to STBTC’s standard
operating procedures. XBiotech will maintain a log of receipt and storage of samples, as well as a log of any testing and results. Study participants will be identified in these logs by their STU. The scientists at XBiotech will retain no other
donor identifiers. All personal identifying information and demographics linked to a participant’s STU will be maintained and secured by STBTC according to their standard operating procedures. The subject’s original informed consent will
be maintained in a secure file at STBTC. This document will only be available to the Principal Investigator, the Clinical Research Manager and any Clinical Research Associates designated to monitor the trial. 

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	Protocol No. 2014-PT028; VER: 1.0		8

  

 All records pertaining to the identity of participants in this research study will be maintained as private
and confidential. Personal identifying information will only be released with the express written permission of the blood donor or by IRB approval. 
 Blood
samples and all records associated with blood samples will be labeled only with a numeric code (STU) that contains no donor personal identifiers. A link does exist between the participant’s name and the numeric code. This link is not available
to staff managing samples at XBiotech. 
  

	7.2	Access to Samples and Donor Information 

 Only XBiotech personnel authorized by the Principal
Investigator will have direct access to study participant’s samples and STU identification number. Other identifying information, such as the informed consent, will only be available to the Principal Investigator, Clinical Research Manager and
any Clinical Research Associates designated to monitor the trial at STBTC. All other study participant identifiers will be retained by STBTC. 
  

	8	Use of Blood Samples 

 Blood samples received by XBiotech will only be used by researchers at XBiotech in
IRB approved clinical trials or for R&D purposes. 
  

	8.1	Restrictions on Sample Usage at the Investigative Site 

 The Investigator/Sponsor, XBiotech,
acknowledges that the conditions for use of this research material are governed by WIRB in accordance with Department of Health and Human Services regulations noted in 45 CFR 46. The Investigator/Sponsor agrees to comply fully with all such
conditions and to report promptly to WIRB any proposed changes in the research project and any unanticipated problems involving risks to subjects or others. The Investigator/Sponsor remains subject to applicable State or local laws or regulations
and institutional policies that provide additional protections for human subjects. This research material may only be used in accordance with the conditions stipulated by WIRB. Any additional use of this material requires prior review and approval
by WIRB. 

  

			
	Confidential Property of XBiotech USA Inc.		November 11th, 2014

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		1

  

			
	STUDY TITLE:		Analysis of Whole Blood from Healthy Individuals to Discover Various Antibodies
		
	PROTOCOL NUMBER:		2010-PT016
		
	PROTOCOL VERSION / DATE:		VER 1.9/ 21 February 2012
		
	SPONSOR/INVESTIGATOR:		XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107
		
			Michael Stecher, M.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107
		
			Sushma Shivaswamy Ph.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107
		
			Seema C Kumar, Ph.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2926
		
	STUDY SITE:		XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		2

  

 TABLE OF CONTENTS 

 

									
	 PROTOCOL SYNOPSIS
		 	3	  
			
	 1
		 BACKGROUND
		 	6	  
			
	 2
		 ELIGIBILITY CRITERIA
		 	6	  
			
	 3
		 INFORMED CONSENT
		 	6	  
			
	 4
		 SAMPLE COLLECTION
		 	7	  
			
	 5
		 SAMPLE PROCESSING AND STORAGE
		 	7	  
				
			5.1		DURATION OF SAMPLE STORAGE		 	7	  
			 5.2
		 VIAL LABELING
		 	7	  
			 5.3
		 SAMPLE PREPARATION
		 	7	  
			
	 6
		 DONOR PRIVACY AND CONFIDENTIALITY
		 	8	  
				
			 6.1
		 RECORD AND SAMPLE HANDLING
		 	8	  
			 6.2
		 ACCESS TO SAMPLES AND DONOR
INFORMATION
		 	9	  
			
	 7
		 USE OF BLOOD SAMPLES
		 	9	  
				
			 7.1
		 DATA AVAILABLE WITH SAMPLES
		 	9	  
			 7.2
		 RESTRICTIONS ON SAMPLE USAGE AT THE
INVESTIGATIVE SITE
		 	9	  

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		3

  

 PROTOCOL SYNOPSIS 

 

					
	Study Title		Analysis of Whole Blood from Healthy Individuals to Discover Various Antibodies
		
	Sponsor		XBiotech USA, Inc.
		
	Investigator/Study Center:		Michael Stecher, M.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107
		
			Sushma Shivaswamy Ph.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-5107
		
			Seema C Kumar, Ph.D.
			XBiotech USA, Inc.
			8201 E Riverside Drive
			Building 4, Suite 100
			Austin, Texas 78744 U.S.A.
			Phone: 512-386-2926
		
	Objectives		Primary Outcome Measures:
			
			 •    
		To determine the frequency of antibodies to cytokines, or other antigens that may have a role in disease pathogenesis, in healthy individuals.
		
			Secondary Objectives:
			
			 •    
		To make B-cell cDNA libraries in order to isolate antibody sequences.
		
	Study Rationale		A better understanding of the role of peripheral blood leukocytes (PBL) in healthy individuals may provide an opportunity to develop new therapies for inflammatory disease. Anti-inflammatory treatments each target the
inflammatory process, but they lack specificity and are associated with a number of undesirable side effects. New biological drugs have emerged that have a greater degree of specificity, but the mechanism for action and long-term benefits remain
unclear.

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		4

  

			
	Trial Design		This is a single center study. The study will be conducted at XBiotech USA, using samples provided by South Texas Blood and Tissue Center (STBTC). The population will consist of up to 1200 healthy participants, accrued at
approximately 100-150 per week. Study participants must be willing to voluntarily consent to having their blood drawn for research purposes.
		
			Each study participant in Phase II will complete a medical history questionnaire and sign an IRB approved informed consent form prior to his or her participation in the study.
		
			The study will consist of two phases; a phase I screening phase and a phase II follow up phase. During phase I, study participants (i.e., Blood donors) will be consented with South Texas Blood and Tissue Center’s standard
informed consent and presented an additional reading material describing the trial and the two phases. Donors will be asked to read the study materials and will have a chance to ask questions regarding the study during their private time with a
trained historian. Verbal informed consent to allow for additional screening of their residual blood samples will be obtained at this time. Donors who opt out will not have their samples screened. Screening samples will be drawn according to STBTC
standard operating procedures and AABB (formerly American Association of Blood Banks) best practices. The residual volume, 2-3 ml of Na-EDTA Plasma will be stored at -65° Celsius pending the screening tests for infectious disease. Only samples
negative for routine blood center blood-borne pathogen testing will be shipped to XBiotech. These samples will be shipped on dry ice via courier to XBiotech in weekly batches. Blood samples will be identified with a unique identification number to
protect the identity of each study participant. Scientists at XBiotech will use these samples to test for the presence of various antibody patterns of interest. Based on the results from the initial screening blood collection, an additional study
visit may be requested by the Sponsor. If an additional visit is requested, phase II will be initiated. Study participants in phase II will be contacted by phone and screened for eligibility by an NIH certified technician for eligibility in phase
II. If they are found to be eligible, they will be asked to schedule a time to come in to STBTC to participate in phase II. At this point, they will be required to sign an IRB-approved consent, and (Phase II-a,) will be asked to complete an
additional health questionnaire provided by XBiotech. If the participant meets inclusion and exclusion criteria, one unit of whole blood will be collected in a sodium citrate bag at STBTC according to STBTC’s standard operating procedures and
will be stored and transported at 4° Celsius (Phase II-b). The sample should be collected early enough in the morning so that it can be shipped, and will arrive via courier at XBiotech within 4 hours
of

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		5

  

					
			being collected. Study participants should also be scheduled such that no more than one participant per any given day will be donating a unit of blood for testing.
		
			Phase I
			Inclusion Criteria:
			
			 1.    
		Healthy male and female individuals between the ages of 18-70
			
			 2.
		Able to read and verbally agree to screening protocol
		
			 Phase II-a (Selection Criteria for Unit Blood Draw)

Inclusion Criteria:

			
			 3.
		Signed and dated institutional review board (IRB)- approved informed consent before any study specific procedures are performed
			
			 4.
		Positive screen for antibody patterns of interest by fluorescent activated cell sorting (FACS) followed by ELISA
		
			Exclusion Criteria:
			
			 1.
		History of bleeding disorders
			
			 2.
		Immunocompromised donors, including participants known to be infected with immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
			
			 3.
		History of viral diseases including hepatitis
			
			 4.
		Diagnosis of anemia
			
			 5.
		Use of Anticoagulants such as coumadin, heparin, plavix, or aspirin greater than 81 mg daily
			
			 6.
		Women who are pregnant or breastfeeding
		
	Approximate Number of Participants		Up to 1200
		
	Analysis Methods		 Phase I -Plasma will be screened for the presence of various antibody patterns of interest. Analysis will involve the use of
fluorescent activated cell sorting (FACS) and Enzyme-linked immunoadsorbant assays (ELISA), similar to technology used by blood centers today for testing blood components.
  

Phase II - B-cells will be sorted and mRNA isolated from them will be used to prepare cDNA libraries.

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		6

  

	1	Background 

 A better understanding of the role of peripheral blood leukocytes (PBL) in healthy
individuals may provide an opportunity to develop new therapies for inflammatory disease. Anti-inflammatory treatments each target the inflammatory process, but they lack specificity and are associated with a number of undesirable side effects. New
biological drugs have emerged that have a greater degree of specificity, but the mechanism for action and long-term benefits remain unclear. 
  

	2	Eligibility Criteria 

 Phase I 

Inclusion Criteria 
  

	 	1.	Healthy male and female individuals between the ages of 18-70 

  

	 	2.	Able to read and verbally agree to screening protocol 

 Phase II (Selection Criteria for Unit
Blood Draw) 
 Inclusion Criteria 
  

	 	3.	Signed and dated institutional review board (IRB)- approved informed consent (Phase II) before any study specific procedures are performed 

 

	 	4.	Positive screen for antibody patterns of interest by fluorescent activated cells sorting (FACS) followed by ELISA 

Phase II 
 Exclusion Criteria 

 

	 	1.	History of bleeding disorders 

  

	 	2.	Immunocompromised donors, including participants known to be infected with immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) 

 

	 	3.	History of viral disease including hepatitis 

  

	 	4.	Diagnosis of anemia 

  

	 	5.	Use of Anticoagulants such as coumadin, heparin, plavix, or aspirin greater than 81 mg daily 

  

	 	6.	Women who are pregnant or breastfeeding 

  

	3	Informed Consent 

 In Phase I of the study, verbal informed consent will be obtained prior to screening
the donor’s blood for antibody patterns of interest. In Phase II of the study, a signed and dated IRB approved informed consent form will be obtained from each participant in accordance with HHS regulations noted in 45 CFR 46.116 prior to
drawing the unit of whole blood. Verbal explanation of the research study including study specific procedures and potential risks will be described in detail by the Investigator or designee. Study participants will have every opportunity to ask
questions regarding his or her participation in the research study as detailed in the informed consent form. All questions and/or concerns will be addressed by the Investigator, or designee, to the satisfaction of

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		7

  

 
the study participant. The original signed consent form along with study specific source documents will be maintained by the Sub-Investigator in a secure file at STBTC. A copy of the original
signed consent form will be given to the study participant. 
 The Investigator/Sponsor will ensure that each study participant’s anonymity will be
maintained in accordance with applicable laws. On study specific source documents submitted to the Investigator/Sponsor by STBTC, study participants will be identified by the Study Unit Identifier (STU) provided by South Texas Blood and Tissue
Center. 
  

	4	Sample Collection 

 Blood samples will be collected from study participants via venipuncture at South
Texas Blood and Tissue Center in San Antonio, Texas. 
  

	5	Sample Processing and Storage 

 Screening samples will be processed and stored at STBTC according to
their standard operating procedures. The residual plasma will be screened for the presence or absence of anti-cytokine antibodies at XBiotech. Analysis will involve the use of fluorescent activated cell sorting (FACS) and Enzyme-linked
immunoadsorbant assays (ELISA). B-cells from the additional unit of whole blood will be sorted, and mRNA isolated from them will be used to prepare cDNA libraries. 
  

	5.1	Duration of Sample Storage 

 Blood samples retained at XBiotech may be stored indefinitely. 

 

	5.2	Vial Labeling 

 Phase I: 

Each sample will be labeled with a study specific unique identification number. The number that will be used is a “Study Unit Identifier” (STU).
Scientists at XBiotech will only have access to the STU, and not to any other donor identifiers, in order to ensure a higher level of participant confidentiality. STBTC phlebotomists will label each sample according to their standard operating
procedures. Any samples that have been separated into new containers or vials by scientists at XBiotech for storage or testing will also be labeled using the STU. 
  

	5.3	Sample Preparation 

 Phase I: 

Samples for initial screening will be drawn according to STBTC standard operating procedures. The residual volume, 2-3 ml of Na-EDTA Plasma will be stored at
-65° Celsius pending the screening tests for infections disease. Only those samples that are negative for blood-borne pathogens will be shipped to XBiotech. These samples will be shipped on dry ice via courier to XBiotech in weekly batches.
Scientists at XBiotech will use these samples to test for the presence of various antibody patterns of interest using a FACS followed by a proprietary ELISA. 

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		8

  

 Phase II: 
 For
study participants in Phase I who screen positive for antibody patterns of interest, one unit of whole blood will be collected in a sodium citrate bag at STBTC and will be stored and transported at 4° Celsius. The sample should be collected
early enough in the morning so that it can be shipped, and will arrive via courier at XBiotech within four hours of being collected. Study participants should also be scheduled such that no more than one participant per any given day will be
donating a unit of blood for testing. Once received, peripheral blood mononuclear cells (PBMCs) from this sample will be isolated, and RNA will be extracted. At this point, the sample can be flash frozen and stored at -80° Celsius for future
testing. The plasma will be stored at -80°C freezer for further testing as well. 
  

	6	Donor Privacy and Confidentiality 

 The Investigator/Sponsor will ensure that each study
participant’s anonymity will be maintained in accordance with applicable laws. On study specific source documents submitted to the Investigator/Sponsor by STBTC, study participants should not be identified by their full name rather by the
specific unique identification number used by South Texas Blood and Tissue Center. Only XBiotech personnel authorized by the Principal Investigator will have direct access to the blood storage facilities and samples. 

 

	6.1	Record and Sample Handling 

 Blood samples arriving at XBiotech, both screening (Phase I) and
units of whole blood (Phase II), will be received and processed only by XBiotech personnel designated by the Principal Investigator. Samples received, stored, and tested by XBiotech employees will only be labeled with a Study Unit Identifier (STU).
This number will be generated according to STBTC’s standard operating procedures. XBiotech will maintain a log of receipt and storage of samples, as well as a log of any testing and results. Study participants will be identified in these logs
by their STU. The scientists at XBiotech will retain no other donor identifiers. For study participants identified from screening as candidates for donation of a unit of whole blood, XBiotech will request this donation from STBTC using the STU.
These participants will be contacted by STBTC. All personal identifying information and demographics linked to a participant’s STU will be maintained and secured by STBTC according to their standard operating procedures. The subject’s
original informed consent will be maintained in a secure file at STBTC. This document will only be available to the Principal Investigator, the Clinical Research Manager and any Clinical Research Associates designated to monitor the trial. 

All records pertaining to the identity of participants in this research study will be maintained as private and confidential. Personal identifying information
will only be released with the express written permission of the blood donor or by IRB approval. 
 Blood samples and all records associated with blood
samples will be labeled only with a numeric code (STU) that contains no donor personal identifiers. A link does exist between the participant’s name and the numeric code. This link is not available to staff managing samples at XBiotech. 

			
	 Confidential Property of XBiotech USA Inc.

Protocol No. 2010-PT016; VER: 1.9
 21 February 2012
		9

  

	6.2	Access to Samples and Donor Information 

 Only XBiotech personnel authorized by the Principal
Investigator will have direct access to study participant’s samples and STU identification number. Other identifying information, such as the informed consent, will only be available to the Principal Investigator, Clinical Research Manager and
any Clinical Research Associates designated to monitor the trial at STBTC. All other study participant identifiers will be retained by STBTC. 
  

	7	Use of Blood Samples 

 Blood samples received by XBiotech will only be used by researchers at XBiotech in
IRB approved clinical trials or for R&D purposes. 
  

	7.1	Data Available With Samples 

 Samples provided by STBTC, in addition to a unique identifier (STU),
will be accompanied by a report detailing the presence or absence of blood-borne pathogens. 
  

	7.2	Restrictions on Sample Usage at the Investigative Site 

 The Investigator/Sponsor, XBiotech,
acknowledges that the conditions for use of this research material are governed by WIRB in accordance with Department of Health and Human Services regulations noted in 45 CFR 46. The Investigator/Sponsor agrees to comply fully with all such
conditions and to report promptly to WIRB any proposed changes in the research project and any unanticipated problems involving risks to subjects or others. The Investigator/Sponsor remains subject to applicable State or local laws or regulations
and institutional policies that provide additional protections for human subjects. This research material may only be used in accordance with the conditions stipulated by WIRB. Any additional use of this material requires prior review and approval
by WIRB.EX-10.11

 Exhibit 10.11 

2015 EQUITY INCENTIVE PLAN 

XBIOTECH INC. 
 ARTICLE 1

 PURPOSE 
  

	1.1	The purpose of this Plan is to promote the interests of XBiotech Inc. (the “Company”) by: 

  

	 	(a)	furnishing certain directors, officers, employees of the Company and its subsidiaries or other persons as the Board of Directors may approve with greater incentive to further develop and promote the business and
financial success of the Company; 

  

	 	(b)	furthering the identity of interests of persons to whom options or share awards may be granted with those of the shareholders of the Company generally through share ownership in the Company; and 

 

	 	(c)	assisting the Company in attracting, retaining and motivating its directors, officers and employees. 

 The
Company believes that these purposes may best be effected by granting Options or Share Awards to acquire Common Shares without par value in the capital of the Company. 

ARTICLE 2 

INTERPRETATION 
  

	2.1	In this Plan, unless there is something in the subject matter or context inconsistent therewith: 

  

	 	(a)	“Affiliate” means any corporation, partnership, joint venture, or other entity during any period in which the Company owns, directly or indirectly, at least twenty percent (20%) of the equity,
voting or profits interest, and any other business venture that the Committee designates in which the Company has a significant interest, as the Committee determines in its discretion; 

 

	 	(b)	“Award” means, individually or collectively, an award of Options, an award of Share Appreciation Rights, Restricted Share Award, Restricted Share Unit Award, or any Performance Share Award granted under
the Plan; 

  

	 	(c)	“Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and
conditions of the Plan; 

  

	 	(d)	 “Blackout Period” means any period during which a Participant is prevented from trading the Common Shares pursuant to a policy of the
Company, including but not limited to the Company’s insider trading policy, as amended and in force 

  
 1 

	 	
from time to time, any lockup or similar agreement described in the First Registration Statement, and any lockup or similar agreement between the Company and a third party restricting the trading
of Common Shares; 

  

	 	(e)	“Board of Directors” means the board of directors of the Company; 

  

	 	(f)	“Business Day” means a day, other than Saturday, Sunday and any other day which is a statutory holiday in the Province of British Columbia, Canada or the State of New York, U.S.A.; 

 

	 	(g)	“Cause” with respect to any Participant, shall mean (i) a Participant’s willful misconduct, (ii) a willful failure of a Participant to perform his or her duties, (iii) a
Participant’s insubordination, theft, dishonesty, or any other willful conduct that is detrimental to the Company or its subsidiaries, (iv) cause for termination of employment or other service contract at common law, or (v) such other
cause as the Board of Directors in good faith reasonably determines provides cause for the discharge of the Participant or termination of the Participant’s relationship with the Company; 

 

	 	(h)	“Change of Control” means: 

  

	 	(i)	the acquisition by any person or persons acting jointly or in concert (as determined by the Securities Act) (“Person”), whether directly or indirectly, of voting securities of the Company that, together with
all other voting securities of the Company held by such Person, constitute in the aggregate more than 50% of all outstanding voting securities of the Company; provided, however, that for purposes of this subparagraph, the acquisition of additional
securities by any one Person, who is considered to own more than 50% of all outstanding voting securities of the Company will not be considered a Change of Control; 

 

	 	(ii)	an amalgamation, arrangement or other form of business combination of the Company with another corporation that results in the holders of voting securities of that other corporation holding, in the aggregate, more than
50% of all outstanding voting securities of the corporation resulting from the business combination; provided, however, that for purposes of this subparagraph, the acquisition of additional securities by any one Person, who is considered to own more
than 50% of all outstanding voting securities of the Company will not be considered a Change of Control; 

  

	 	(iii)	 a change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired
during the twelve (12) month period ending on the date of the most recent acquisition by such person or 

  
 2 

	 	
persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company
immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subparagraph (iii), the following will not constitute a change in the ownership of a substantial portion of the Company’s assets: (A) a
transfer to a Related Entity, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company’s stock, (2) an entity of which
the Company has Control, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity of which a Person described in
subparagraph (iii)(B)(3) has Control. For purposes of this subparagraph (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities
associated with such assets; or 

  

	 	(iv)	any other transaction that is deemed to be a “Change of Control” for the purposes of this Plan by the Board of Directors, in its sole discretion; 

Notwithstanding the foregoing, a transaction will not be deemed a Change of Control for Awards granted to Participants who are subject to U.S. taxation unless
the transaction qualifies as a Change of Control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and U.S. Internal Revenue Service guidance that
has been promulgated or may be promulgated thereunder from time to time. Further and for the avoidance of doubt, a transaction will not constitute a Change of Control if: (x) its sole purpose is to change the state or jurisdiction of the
Company’s incorporation, or (y) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. 

 

	 	(i)	“CEO” means the Chief Executive Officer of the Company; 

  

	 	(j)	“Code” means the U.S. Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder shall include such section or regulation, any valid regulation
promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation; 

 

	 	(k)	“Committee” means a committee of directors or of other individuals satisfying applicable laws appointed by the Board of Directors, or a duly authorized committee of the Board of Directors, in accordance
with Article 3 hereof; 

  
 3 

	 	(l)	“Common Share” means a common share without par value in the capital of the Company; 

  

	 	(m)	“Consultant” means a person other than an employee, officer or director of the Company or of any of its subsidiaries that is engaged to provide ongoing valuable services to the Company or an Affiliate;

  

	 	(n)	“Control” by a person over a second person means the power to direct, directly or indirectly, the management and policies of the second person by virtue of: (i) ownership of or direction over
voting securities in the second person; (ii) a written agreement or indenture; (iii) being or Controlling the general partner or manager of the second person; or (iv) being a trustee of the second person; 

 

	 	(o)	“Effective Date” has the meaning under paragraph 11.1 of the Plan. 

  

	 	(p)	“Eligible Persons” means directors, officers, employees or Consultants of the Company or of any of its subsidiaries, and an “Eligible Person” shall have a corresponding meaning;

  

	 	(q)	“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended; 

  

	 	(r)	“Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and
different terms), awards of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Board of Directors, and/or
(iii) the exercise price of an outstanding Award is increased or reduced. The Board of Directors will determine the terms and conditions of any Exchange Program, in its sole discretion; 

 

	 	(s)	“Exercise Price” means the price per share at which Common Shares may be subscribed for by a Participant pursuant to a particular Share Option Agreement, as further described under paragraph 7.1(c)
of the Plan; 

  

	 	(t)	 “Fair Market Value Price” means, as applied to a specific date, the price of a Common Share that is based on the opening, closing,
actual, high, low or average selling prices of a Common Share reported on any established stock exchange or national market system including without limitation the New York Stock Exchange and the National Market System of the National Association of
Securities Dealers, Inc. Automated Quotation System on the applicable date, the preceding trading day, the next succeeding trading day, or an average of trading days, as determined by the Board in its discretion. Unless otherwise specified in an
Award Agreement, Fair Market Value shall be deemed to be equal to the closing price of a Common Share on the relevant date, or if no sales of Common Shares shall have occurred on the applicable date the closing price of the Common Shares on the next
preceding date on which there were such sales. Notwithstanding the foregoing, if Common Shares are not traded on any established stock exchange or national market system, the Fair Market Value

  
 4 

	 	
means the price of a Common Share as established by the Board acting in good faith based on a reasonable valuation method that is consistent with the requirements of Section 409A of the Code
and the regulations thereunder. Notwithstanding the foregoing, for purposes of any Awards granted on the Registration Date, the Fair Market Value Price will be the initial price to the public as set forth in the final prospectus included within the
registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission for the initial public offering of the Company’s Common Shares; 

  

	 	(u)	“First Registration Statement” means the first registration statement that is filed by the Company and declared effective pursuant to Section 12(g) of the Exchange Act, with respect to any class of
the Company’s securities; 

  

	 	(v)	“Fiscal Year” means the fiscal year of the Company; 

  

	 	(w)	“Incentive Share Option” means an Option to purchase Common Shares with the intention that it qualify as an “incentive stock option” within the meaning of Section 422 of the Code and the
regulations and guidance promulgated thereunder, such intention being evidenced by the resolutions of the directors at the time of grant; 

  

	 	(x)	“Optioned Shares” means the Common Shares that may be subscribed for by a Participant pursuant to a Share Option Agreement; 

 

	 	(y)	“Options” means share options granted hereunder to purchase Common Shares from treasury; 

  

	 	(z)	“Outside Director” means a director who is not an employee (including officer) of the Company or an Affiliate; 

  

	 	(aa)	“Nonqualified Share Option” means an Option to purchase Common Shares other than an Incentive Share Option; 

  

	 	(bb)	“Participant” means an Eligible Person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award; 

 

	 	(cc)	“Performance Criteria” means the one or more criteria that the Board of Directors shall select for purposes of establishing the performance goals for a Performance Period; 

 

	 	(dd)	“Performance Period” means one or more periods of time, which may be of varying and overlapping duration, as the Board of Directors may select, over which the attainment of one or more performance goals
will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance Share Award. 

  

	 	(ee)	“Performance Share Award” means an award of Common Shares which is granted pursuant to the terms and conditions of Article 9; 

  
 5 

	 	(ff)	“Plan” means this 2015 Equity Incentive Plan, as the same may from time to time be supplemented, amended and/or restated and in effect; 

 

	 	(gg)	“Registration Date” means the effective date of the First Registration Statement; 

  

	 	(hh)	“Related Entity” means, for a company or corporation, a Person that Controls or is Controlled by the Company or that is Controlled by the same Person that controls that company or corporation;

  

	 	(ii)	“Restricted Share Award” means an award of Common Shares which is granted pursuant to the terms and conditions of Article 9; 

 

	 	(jj)	“Restricted Share Unit Award” means a bookkeeping entry representing an amount equal to the Fair Market Value of one Common Share, granted pursuant to the terms and conditions of Article 9;

  

	 	(kk)	“Retirement” means retirement as an employee and/or officer of the Company, and if there is any question on whether a cessation of employment is by way of a retirement or not, the determination by the
CEO (or in the CEO’s absence or in the case of a situation involving the cessation of employment of an executive officer of the Company, the Compensation Committee of the Board of Directors or the independent members of the Board of Directors)
shall be conclusive and binding on the Participant; 

  

	 	(ll)	“Rule 16b-3” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan; 

 

	 	(mm)	“Section 16(b)” means Section 16(b) of the Exchange Act; 

  

	 	(nn)	“Securities Act” means the Securities Act (British Columbia); 

  

	 	(oo)	“Share Appreciation Right” means a right to receive the appreciation on Common Shares that is granted pursuant to the terms and conditions of Article 9; 

 

	 	(pp)	“Share Award” means any Restricted Share Award, Restricted Share Unit Award, Share Appreciation Right, Performance Share Award, or any Other Share Award granted under the Plan; 

 

	 	(qq)	“Stock Exchanges” means such stock exchanges or other organized market on which the Common Shares are listed or posted for trading, including the NASDAQ Stock Market LLC; and 

 

	 	(rr)	“Subsidiary” has the meaning assigned thereto under the Securities Act (British Columbia) as the same may from time to time be amended or re-enacted. 

 

	2.2	Any question arising as to the interpretation of this Plan will be determined by the Board of Directors and, absent manifest error, such determination will be conclusive and binding on the Company and all Participants.

  
 6 

	2.3	In this Plan, words importing the singular number only include the plural and vice versa, words importing any gender include all genders and words importing persons include individuals, corporations, limited and
unlimited liability companies, general and unlimited partnerships, associations, trusts, incorporated organizations, joint ventures and governmental authorities. 

ARTICLE 3 

ADMINISTRATION OF PLAN 
  

	3.1	This Plan will be administered by the Board of Directors. The Board of Directors may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a
Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board of Directors that have been delegated to the Committee, including the power to delegate to a subcommittee of the
Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board of Directors will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers
will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board of Directors or the Committee (as applicable). The Board of Directors may retain the authority to concurrently administer the
Plan with the Committee and may, at any time, revest to the Board of Directors some or all of the powers previously delegated. For the purpose of delegation of administration of the Plan, one or more of the CEO and/or officers of the Company, if
designated by the Board of Directors, will be deemed a Committee. 

  

	3.2	To the extent that the Board of Directors determines it to be desirable to qualify Awards granted hereunder as “performance-based compensation” within the meaning of Section 162(m) of the Code, the Plan
will be administered by a Committee of two (2) or more “outside directors” within the meaning of Section 162(m) of the Code. To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the
transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3. 

  

	3.3	The Board of Directors will take such steps which in its opinion are required to ensure that the Committee to which it has delegated the power to ensure that it has the necessary authority to fulfill its functions under
this Plan. 

  

	3.4	Subject to the provisions of the Plan, the Board of Directors, and in the case of a Committee, subject to the specific duties delegated by the Board of Directors to such Committee, will have the authority, in its
discretion: 

  

	 	(a)	to determine the Fair Market Value Price; 

  

	 	(b)	to select the Eligible Persons to whom Awards may be granted hereunder; 

  

	 	(c)	to determine the number of Common Shares to be covered by each Award granted hereunder; 

  
 7 

	 	(d)	to approve forms of Award Agreements for use under the Plan; 

  

	 	(e)	to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when
Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such
factors as the Board of Directors (or Committee appointed by the Board of Directors) will determine; 

  

	 	(f)	to institute and determine the terms and conditions of an Exchange Program; 

  

	 	(g)	to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; 

  

	 	(h)	to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws or for qualifying for
favorable tax treatment under applicable foreign laws; 

  

	 	(i)	to modify or amend each Award (subject to Article 11 of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards and to extend the maximum
term of an Option (subject to paragraph 8.1(d) of the Plan regarding Incentive Share Options); 

  

	 	(j)	to allow to satisfy withholding tax obligations in such manner as prescribed in paragraph 10.6 of the Plan; 

  

	 	(k)	to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Board of Directors; 

 

	 	(l)	to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant, as applicable, under an Award; and 

 

	 	(m)	to make all other determinations deemed necessary or advisable for administering the Plan. 

  

	3.5	The Board of Directors has the authority to determine all questions arising out of the Plan and any Award granted pursuant to the Plan, which interpretations and determinations will be conclusive and binding on the
Company and all other affected persons. 

  
 8 

 ARTICLE 4 

REGULATIONS 
  

	4.1	The Board of Directors may from time to time establish such regulations, make such determinations and interpretations and take such steps in connection with this Plan which, in its opinion, are necessary or desirable
for the administration of this Plan. 

 ARTICLE 5 

COMPLIANCE WITH LAWS 
  

	5.1	The Plan, the grant, exercise, vesting, and/or settlement of Awards under the Plan and the Company’s obligation to issue Common Shares on exercise, vesting, or settlement of Awards will be subject to all applicable
federal, provincial and foreign laws, rules and regulations and the rules of any regulatory authority or Stock Exchange on which the securities of the Company are listed. The Company shall not be required, or in any way obliged, to grant Awards or
issue Common Shares if such grant or issuance would require registration of the Plan or of any Awards or Common Shares under the securities laws of any jurisdiction other than Canada or the United States. Common Shares issued to a Participant
pursuant to the exercise, vesting, or settlement of an Award may be subject to limitations on sale or resale under applicable securities laws. 

  

	5.2	The Board of Directors may from time to time take such steps and require such documentation from Eligible Persons or Participants which in its opinion are necessary or desirable to ensure compliance with all applicable
laws, the bylaws, rules and regulations of any Stock Exchanges. 

  

	5.3	The Board of Directors may also from time to time take such steps which in its opinion are necessary or desirable to restrict the transferability of any Common Shares acquired on the exercise, vesting, or settlement of
any Award in order to ensure such compliance, including, where applicable, the endorsement of a legend on any certificate representing Common Shares acquired on the exercise, vesting, or settlement of any Award to the effect that such Common Shares
may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or the United States. 

ARTICLE 6 
 COMMON SHARES
SUBJECT TO PLAN 
  

	6.1	Subject to adjustment provided for herein, the number of Common Shares that may be issued pursuant to the Plan for the period from the Effective Date will be one million (1,000,000) Common Shares, all of which may
be issued pursuant to the exercise of Incentive Stock Options (the “Share Reserve”). 

  

	6.2	The Board of Directors will reserve for allotment from time to time out of the authorized but unissued Common Shares sufficient Common Shares to provide for issuance of all Common Shares which are issuable under all
outstanding Options or Share Awards. 

  
 9 

	6.3	Upon the expiry or termination of an Award which has not been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to a Restricted Share Award, Restricted Share Unit Award, or Performance
Share Award is forfeited to or repurchased by the Company due to failure to vest, the number of unpurchased Common Shares reserved for issuance under that Award (or for Awards other than Options or Share Appreciation Rights the forfeited or
repurchased Common Shares) shall become available for issue for the purpose of additional Awards which may be granted under this Plan (unless the Plan has terminated). With respect to Share Appreciation Rights, only Common Shares actually issued
(i.e., the net Common Shares issued) pursuant to a Share Appreciation Right will cease to be available under the Plan; all remaining Common Shares under Share Appreciation Rights will remain available for future grant or sale under the Plan (unless
the Plan has terminated). Common Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued
pursuant to Restricted Share Awards, Restricted Share Unit Awards, or Performance Share Awards are repurchased by the Company or are forfeited to the Company, such Common Shares will become available for future grant under the Plan. Common Shares
used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Common
Shares, such cash payment will not result in reducing the number of Common Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in paragraph 10.3, the maximum number of Common Shares
that may be issued upon the exercise of Incentive Share Options will equal the aggregate Common Share number stated in the first sentence of paragraph 6.1, plus, to the extent allowable under Section 422 of the Code and the Treasury
Regulations promulgated thereunder, any Common Shares that become available for issuance under the Plan pursuant to the first sentence of paragraph 6.1 and this paragraph 6.3. 

 

	6.4	Participation in this Plan will be entirely voluntary and any decision not to participate will not affect an Eligible Person’s employment or other service relationship with the Company or any Related Entity.

  

	6.5	Nothing in this Plan or in any Award Agreement will confer on any Participant any right to remain as an employee, officer, director or Consultant of the Company or any Related Entity. 

 

	6.6	Nothing herein or otherwise shall be construed so as to confer on any Participant any rights as a shareholder of the Company with respect to any Common Shares reserved for the purpose of any Award. 

 

	6.7	A Participant will only have rights as a shareholder of the Company with respect to Shares that the Participant acquires through the exercise of an Option in accordance with its terms. 

  
 10 

	6.8	A holder of a Share Award will only have rights as a shareholder of the Company with respect to the Common Shares subject to the Share Award as specified and subject to restrictions as set out in the relevant agreement
evidencing such Share Award. 

 ARTICLE 7 

GRANT OF OPTIONS 
  

	7.1	Subject to the rules set out below, the Board of Directors may from time to time grant to any Eligible Person one or more Options as the Board of Directors deems appropriate: 

 

	 	(a)	Date Option Granted. The date on which an Option will be deemed to have been granted under this Plan will be the date on which the Board of Directors authorizes the grant of such Option or such other date as may
be specified by the Board of Directors at the time of such authorization. 

  

	 	(b)	Number of Common Shares. The number of Common Shares that may be purchased under any Option by a Participant will be determined by the Board of Directors provided that such number may not be greater than the
maximum number permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchanges. A Participant, at the time of granting an Option, may hold more than one Option.

  

	 	(c)	Exercise Price. The exercise price (the “Exercise Price”) per Common Share under each Option will be determined by the Board of Directors by reference to the fair market price(s) of the Common Shares on
the primary Stock Exchange for which most trading of the Common Shares occurs, generally by reference to the closing market price of the Common Shares, provided that such price may not be less than the lowest price permitted under the applicable
rules and regulations of all regulatory authorities to which the Company is subject, including those of the Stock Exchanges. Notwithstanding the foregoing, in the case of a Nonqualified Share Option or Incentive Share Option, the Exercise Price will
be no less than one hundred percent (100%) of the Fair Market Value Price per Common Share on the date of grant, subject to the limitations applicable to Incentive Share Options set forth in paragraph 8.1(b) of the Plan. Notwithstanding
the foregoing, Options may be granted with a per Share exercise price of less than one hundred percent (100%) of the Fair Market Value Price per Common Share on the date of grant pursuant to a transaction described in, and in a manner
consistent with, Section 424(a) of the Code. 

  

	 	(d)	Award Agreement. Each Option will be evidenced by an Award Agreement, which incorporates such terms and conditions as the Board of Directors, in its discretion, deems appropriate and consistent with the
provisions of this Plan. Each Award Agreement will be executed by the Eligible Person to whom the Option is granted and on behalf of the Company by any member of the Board of Directors, the CEO or the Corporate Secretary of the Company or such other
person as the Board of Directors may designate for such purpose. 

  
 11 

	 	(e)	Expiry of Options. Each Option will expire on the earlier of: 

  

	 	(i)	the date determined by the Board of Directors and specified in the Award Agreement pursuant to which such Option is granted, provided that such date may not be later than the earlier of (A) the date which is the
tenth anniversary of the date on which such Option is granted (except (1) in the circumstances where the tenth anniversary falls within, or within five Business Days after, the end of a Blackout Period, then instead of the tenth anniversary,
the relevant date shall be the fifth Business Day after the end of such Blackout Period; provided, however, that the extension in this subparagraph (e)(i)(A)(1) shall be applied to any Option held by a Participant who is a U.S. taxpayer only to
the extent that it would not violate Code Section 409A and (2) in the circumstances described in paragraph 8.1(b) of the Plan) and (B) the latest date permitted under the applicable rules and regulations of all regulatory
authorities to which the Company is subject, including the Stock Exchanges; 

  

	 	(ii)	in the event the Participant ceases to be an Eligible Person for any reason, other than death of the Participant, such period of time after the date on which the Participant ceases to be an Eligible Person as may be
specified by the Board of Directors, which period may be specified in the specific Award Agreement with respect to such Option (but in no event granted beyond the original expiry date of the Option as provided for in subparagraph (i) above). In
the absence of a specified time in the Award Agreement, the Option will remain exercisable for 90 days following the date the Participant ceases to be an Eligible Person due to termination without Cause or resignation (or 180 days following the
date Participant ceases to be an Eligible Person due to such Participant’s Retirement, 365 days following the date Participant ceases to be an Eligible Person due to such Participant’s disability, and immediately upon Participant
ceasing to be an Eligible Person due to the termination of such Participant as an Eligible Person for Cause). Unless otherwise provided by the Board of Directors, if on the date the Participant ceases to be an Eligible Person, the Participant is not
vested as to his or her entire Option, the Common Shares covered by the unvested portion of the Option will revert to the Plan. If after the date the Participant ceases to be an Eligible Person, the Participant does not exercise his or her Option
within the time specified by the Board of Directors, the Option will terminate, and the Common Shares covered by such Option will revert to the Plan; 

  

	 	(iii)	 in the case of the death of a Participant prior to: (A) the Participant ceasing to be an Eligible Person; or (B) the date which is the

  
 12 

	 	
number of days determined under subparagraph (ii) above, from the date on which the Participant ceased to be an Eligible Person; the date which is the 365th day after the date of death of
such Participant or such other date as may be specified by the Board of Directors and which period will be specified in the Award Agreement with respect to such Option (but in no event beyond the original expiry date of the Option as provided for in
subparagraph (i) above). Unless otherwise provided by the Board of Directors, if at the time of death Participant is not vested as to his or her entire Option, the Common Shares covered by the unvested portion of the Option will immediately
revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will terminate, and the Common Shares covered by such Option will revert to the Plan; 

 

	 	(iv)	notwithstanding the foregoing provisions of subparagraphs (ii) and (iii) of this paragraph 7.1(e), the Board of Directors may, subject to regulatory approval, at any time prior to expiry of an Option
extend the period of time within which an Option held by a deceased Participant may be exercised or within which an Option may be exercised by an Participant who has ceased to be an Eligible Person, but such an extension shall not be granted beyond
the original expiry date of the Option as provided for in subparagraph (i) above; and 

  

	 	(v)	notwithstanding the foregoing provisions, if the expiry of an Option pursuant to subparagraphs (ii) and (iii) of this paragraph 7.1(e) occurs during the Blackout Period applicable to the Participant or
within five Business Days after the last day of a Blackout Period applicable to the Participant, the expiry date for the Option will be the last day of such five Business Day period, except in the event of expiry of Options following termination of
a Participant’s employment or services (for a director) or contract as a Consultant for Cause. 

  

	 	(f)	Exercise of Options. 

  

	 	(i)	The Board of Directors may impose such limitations or conditions on the exercise or vesting of any Option as the Board of Directors, in its discretion, deems appropriate. Each Award Agreement will provide that the
Option granted thereunder may be exercised by notice signed by the Participant and accompanied by full payment for the Common Shares being purchased or by other means, including without limitation electronic means via on-line arrangements, as the
Board of Directors may from time to time approve and allow. 

  
 13 

	 	(ii)	The Board of Directors will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Board of Directors will determine the
acceptable form of consideration at the time of grant. Such consideration may consist entirely of: (A) cash; (B) cheque; (C) other Common Shares, provided that such Common Shares have a Fair Market Value Price on the date of surrender
equal to the aggregate exercise price of the Common Shares as to which such Option will be exercised and provided that accepting such Common Shares will not result in any adverse accounting consequences to the Company, as the Board of Directors
determines in its sole discretion; (D) consideration received by the Company under a broker-assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan;
(E) by net exercise; (F) such other consideration and method of payment for the issuance of Common Shares to the extent permitted by the applicable securities laws and all applicable rules and regulations of all regulatory authorities to
which the Company is subject; or (G) any combination of the foregoing methods of payment. 

 ARTICLE 8 

INCENTIVE SHARE OPTION LIMITATIONS 
  

	8.1	To the extent required by Section 422 of the Code, if applicable, Incentive Share Options shall be subject to the following additional terms and conditions and if there is any conflict between the terms of this
Article and other provisions under the Plan, the provisions under this Article shall prevail: 

  

	 	(a)	Dollar Limitation. To the extent the aggregate Fair Market Value Price (determined as of the grant date) of Common Shares with respect to which Incentive Share Options are exercisable for the first time during
any calendar year (under the Plan and all other Share option plans of the Company) exceeds U.S. $100,000, such portion in excess of U.S. $100,000 shall be treated as a Nonqualified Share Option. In the event the Participant holds two or more such
Options that become exercisable for the first time in the same calendar year, such limitation shall be applied on the basis of the order in which such Options are granted. 

 

	 	(b)	10% Shareholders. If a Participant owns 10% or more of the total voting power of all classes of the Company’s shares, then the exercise price per share of an Incentive Share Option shall not be less than
110% of the fair market value of the Common Shares on the grant date and the Option term shall not exceed five years. The determination of 10% ownership shall be made in accordance with Section 422 of the Code. 

  
 14 

	 	(c)	Eligible Employees. Eligible Persons who are not employees of the Company or one of its parent corporations or subsidiary corporations may not be granted Incentive Share Options. For purposes of this
paragraph (c), “parent corporation” and “subsidiary corporation” shall have the meanings attributed to those terms for purposes of Section 424 of the Code. 

 

	 	(d)	Term. The term of an Incentive Share Option shall not exceed 10 years. 

  

	 	(e)	Exercisability. To qualify for Incentive Share Option tax treatment, an Option designated as an Incentive Share Option must be exercised within three months after termination of employment for reasons other than
death, except that, in the case of termination of employment due to total disability, such Option must be exercised within one year after such termination. Employment shall not be deemed to continue beyond the first 90 days of a leave of
absence unless the Participant reemployment rights are guaranteed by statute or contract. For purposes of this subparagraph (e), “total disability” shall mean a mental or physical impairment of the Participant which is expected to result
in death or which has lasted or is expected to last for a continuous period of 12 months or more and which causes the Participant to be unable, in the opinion of the Company and two independent physicians, to perform his or her duties for the
Company and to be engaged in any substantial gainful activity. Total disability shall be deemed to have occurred on the first day after the Company and the two independent physicians have furnished their opinion of total disability to the Board of
Directors. 

  

	 	(f)	Assignability. No Incentive Share Option granted under the Plan may be assigned or transferred by the Participant other than by will or by the laws of descent and distribution, and during the Participant’s
lifetime, such Incentive Share Option may be exercised only by the Participant. 

  

	 	(g)	Grant. No Incentive Share Options may be granted more than ten years after the later of (i) the adoption of the Plan by the Board and (ii) the adoption by the Board of any amendment to the Plan that
constitutes the adoption of a new plan for purposes of Section 422 of the Code. 

 ARTICLE 9 

PROVISIONS OF SHARE AWARDS OTHER THAN OPTIONS. 

The Board of Directors may in its discretion determine to grant other forms of Awards other than Options under this Plan on the terms and conditions set out
below and all such other forms of share awards will be subject to the Share Reserve: 
  

	9.1	Restricted Share Awards. 

  

	 	(a)	 Each Restricted Share Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Board of Directors shall deem
appropriate. The terms and conditions of each Award Agreement evidencing a 

  
 15 

	 	
Restricted Share Award may change from time to time, and the terms and conditions of separate Restricted Share Award need not be identical, provided, however, that each Award Agreement evidencing
a Restricted Share Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

 

	 	(i)	Consideration. A Restricted Share Award may be awarded in consideration for (A) cash, cheque, bank draft or money order payable to the Company; (B) past services actually rendered to the Company or an
Affiliate; or (C) any other form of legal consideration that may be acceptable to the Board of Directors, in its sole discretion, and permissible under applicable law. 

 

	 	(ii)	Vesting; Other Restrictions. Common Shares subject to a Restricted Share Award may be subject to forfeiture to or repurchase by the Company in accordance with a vesting schedule or other restrictions to be
determined by the Board of Directors as specified in the Award Agreement evidencing the Restricted Share Award. Except as otherwise provided in this Plan, Common Shares subject to the Restricted Share Award will be released from escrow as soon as
practicable after such Common Shares vest or the restrictions lapse or at such other time as the Board of Directors may determine. The Board of Directors, in its discretion, may accelerate the time at which any vesting conditions or other
restrictions will lapse or be removed. On the date set forth in the Award Agreement, the Restricted Share Award for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.

  

	 	(iii)	Voting Rights; Dividend and Other Distributions. Before the Common Shares subject to a Restricted Share Award vest or are otherwise subject to restrictions, Participants holding Common Shares subject to the
Restricted Share Award granted hereunder (A) may exercise full voting rights with respect to those Common Shares, unless the Board of Directors determines otherwise and (B) will be entitled to receive all dividends and other distributions
paid with respect to such Common Shares, unless the Board of Directors provides otherwise. If any such dividends or distributions are paid in Common Shares, the Common Shares will be subject to the same restrictions on transferability and
forfeitability as the Common Shares subject to the Restricted Share Award with respect to which they were paid. 

  

	9.2	Restricted Share Unit Awards. 

  

	 	(a)	 Each Restricted Share Unit Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Board of Directors shall
deem 

  
 16 

	 	
appropriate. The terms and conditions of each Award Agreement evidencing a Restricted Share Unit Award may change from time to time, and the terms and conditions of separate Restricted Share Unit
Award need not be identical, provided, however, that each Award Agreement evidencing a Restricted Share Unit Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of
the following provisions: 

  

	 	(i)	Consideration. At the time of grant of a Restricted Share Unit Award, the Board of Directors will determine the consideration, if any, to be paid by the Participant upon delivery of each Common Share subject to
the Restricted Share Unit Award. The consideration to be paid (if any) by the Participant for each Common Share subject to a Restricted Share Unit Award may be paid in any form of legal consideration that may be acceptable to the Board of Directors
in its sole discretion and permissible under applicable law. 

  

	 	(ii)	Vesting. At the time of the grant of a Restricted Share Unit Award, the Board of Directors may impose such restrictions or conditions to the vesting of the Restricted Share Unit Award as it, in its sole
discretion, deems appropriate. The Board of Directors, in its discretion, may accelerate the time at which any vesting conditions or other restrictions will lapse or be removed. On the date set forth in the Award Agreement, the Restricted Share Unit
Award for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. Except as otherwise provided in the applicable Award Agreement, such portion of the Restricted Share Unit Award that
has not vested will be forfeited upon the Participant’s termination of services or employment or engagement with the Company. 

  

	 	(iii)	Payment. Upon meeting the applicable vesting criteria, a Restricted Share Unit Award (or vested portion thereof) may be settled by the delivery of Common Shares, its cash equivalent, or in any combination
thereof, as determined by the Board of Directors and contained in the Award Agreement evidencing the Restricted Share Unit Award. 

  

	 	(iv)	Additional Restrictions. At the time of the grant of a Restricted Share Unit Award, the Board of Directors, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the
Common Shares (or their cash equivalent) subject to a Restricted Share Unit Award to a time after the vesting of such Restricted Share Unit Award. 

  
 17 

	 	(v)	Dividend Equivalents. Dividend equivalents may be credited in respect of Common Shares covered by a Restricted Share Unit Award, as determined by the Board of Directors and contained in the Award Agreement
evidencing Restricted Share Units. At the sole discretion of the Board of Directors, such dividend equivalents may be converted into additional Common Shares covered by the Restricted Share Unit Award in such manner as determined by the Board of
Directors. Any additional Common Shares covered by the Restricted Share Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Award Agreement to which they relate.

  

	9.3	Share Appreciation Rights. 

  

	 	(a)	Each Share Appreciation Rights Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Board of Directors shall deem appropriate. The terms and conditions of each Award
Agreement evidencing a Share Appreciation Rights Award may change from time to time, and the terms and conditions of separate Share Appreciation Right Award need not be identical, provided, however, that each Award Agreement evidencing a Share
Appreciation Rights Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

 

	 	(i)	Term. No Share Appreciation Right shall be exercisable after the expiration of ten (10) years from the date of its grant or such shorter period specified in the Share Appreciation Right Agreement.

  

	 	(ii)	Exercise Price. The exercise under each Share Appreciation Right will be determined by the Board of Directors by reference to the fair market price(s) of the Common Shares on the primary Stock Exchange for which
most trading of the Common Shares occurs, generally by reference to the closing market price of the Common Shares, provided that such price may not be less than one hundred percent (100%) of the Fair Market Value Price per Common Share on the
date of grant. 

  

	 	(iii)	Calculation of Appreciation. The appreciation distribution payable on the exercise of a Share Appreciation Right will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value
Price (on the date of the exercise of the Share Appreciation Right) of a number of Common Shares equal to the number of Common Share equivalents in which the Participant is vested under such Share Appreciation Right, and with respect to which the
Participant is exercising the Share Appreciation Right on such date, over (B) the aggregate Exercise Price of such number of Common Share equivalents being exercised. 

  
 18 

	 	(iv)	Vesting. At the time of the grant of a Share Appreciation Right, the Board of Directors may impose such restrictions or conditions to the vesting of such Share Appreciation Right as it, in its sole discretion,
deems appropriate. 

  

	 	(v)	Exercise. To exercise any outstanding Share Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such
Share Appreciation Right. 

  

	 	(vi)	Payment. The appreciation distribution in respect of a Share Appreciation Right may be paid in Common Shares, in cash, in any combination of the two or in any other form of consideration, as determined by the
Board of Directors and set forth in the Award Agreement evidencing such Share Appreciation Right. 

  

	 	(vii)	Expiry of Share Appreciation Rights. Each Share Appreciation Right will expire upon the date determined by the Board of Directors, in its sole discretion, and set forth in the Award Agreement evidencing Share
Appreciation Rights. Notwithstanding the foregoing, the rules of subparagraph (e) of paragraph 7.1 also will apply to Share Appreciation Rights. 

  

	9.4	Performance Share Awards. 

  

	 	(a)	Each Performance Share Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Board of Directors shall deem appropriate. The terms and conditions of each Award Agreement
evidencing a Performance Share Award may change from time to time, and the terms and conditions of separate Performance Share Award need not be identical, provided, however, that each Award Agreement evidencing a Performance Share Award shall
conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

  

	 	(i)	 Performance Objectives and Other Terms. The Board of Directors will set performance objectives or other vesting provisions (including, without
limitation, continued status as an Eligible Person) in its discretion which, depending on the extent to which they are met, will determine the number or value of Common Shares subject to a Performance Share Award that will be paid out to the
Participant. The time period during which the performance objectives or other vesting provisions must be met will be called the “Performance Period.” Each Performance Share Award will be evidenced by an Award Agreement that will specify

  
 19 

	 	
the Performance Period, and such other terms and conditions as the Board of Directors, in its sole discretion, will determine. The Board of Directors may set performance objectives based upon the
achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal, provincial or state securities laws, or any other basis determined by the Board of
Directors in its discretion. 

  

	 	(ii)	Vesting. After the applicable Performance Period has ended, the holder of Performance Share Award will be entitled to receive a payout of the number of Common Shares subject to the Performance Share Award earned
by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Share Award, the Board of
Directors, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Common Shares subject to the Performance Share Award. 

 

	 	(iii)	Payment. Upon meeting the applicable vesting criteria, a Performance Share Award (or vested portion thereof) may be settled by the delivery of Common Shares, its cash equivalent, or in any combination thereof, as
determined by the Board of Directors and contained in the Award Agreement evidencing the Performance Share Award. 

  

	 	(iv)	Expiry of Performance Share Award. On the date set forth in the Award Agreement, all unearned or unvested Common Shares subject to a Performance Share Award will be forfeited to the Company, and again will be
available for grant under the Plan. 

 ARTICLE 10 

PROVISIONS APPLICABLE TO AWARDS 
  

	10.1	Leave of Absence/Transfer Between Locations. Unless the Board of Directors provides otherwise and subject to applicable laws, vesting of Awards granted hereunder will be suspended during any unpaid leave of
absence. A Participant will not cease to be an employee in the case of (a) any leave of absence approved by the Company, (b) transfers between locations of the Company or between the Company, its parent, or any subsidiary, or (c) any
statutory-protected leave. For purposes of Incentive Share Options, no such leave may exceed 3 months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence
approved by the Company is not so guaranteed, then 6 months following the 1st day of such leave any Incentive Share Option held by the Participant will cease to be treated as an Incentive Share Option and will be treated for U.S. tax purposes as a
Nonqualified Share Option. 

  
 20 

	10.2	Restrictions on Transfer. Unless the Board of Directors provides otherwise, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws
of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Board of Directors makes an Award transferable, such Award will contain such additional terms and conditions as the Board of
Directors deems appropriate. 

  

	10.3	Adjustments; Dissolution or Liquidation; Merger or Change of Control. 

  

	 	(a)	Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Common Shares, other securities, or other property), recapitalization, stock split, reverse stock split,
reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Common Shares occurs, the
Board of Directors, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Common Shares that may be delivered under the Plan and/or the
number, class, and price of Common Shares covered by each outstanding Award, and the Share Reserve. 

  

	 	(b)	Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Board of Directors will notify each Participant as soon as practicable prior to the effective date of such
proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action. 

  

	 	(c)	 Change of Control. Subject to the immediately following paragraph, in the event of a merger of the Company with or into another corporation or
other entity or a Change of Control, each outstanding Award will be treated as the Board of Directors determines, including, without limitation, that (i) Awards may be assumed, or substantially equivalent Awards will be substituted, by the
acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant’s Awards will terminate upon or
immediately prior to the consummation of such merger or Change of Control; (iii) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or
upon consummation of such merger or Change of Control, and, to the extent the Board of Directors determines, terminate upon or immediately prior to the effectiveness of such merger or Change of Control; (iv) (A) the termination of an Award
in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant’s rights as of the date of the occurrence of the transaction (and,
for the 

  
 21 

	 	
avoidance of doubt, if as of the date of the occurrence of the transaction the Board of Directors determines in good faith that no amount would have been attained upon the exercise of such Award
or realization of the Participant’s rights, then such Award may be terminated by the Company without payment), or (B) the replacement of such Award with other rights or property selected by the Board of Directors in its sole discretion; or
(v) any combination of the foregoing. In taking any of the actions permitted under this subparagraph (c), the Board of Directors will not be required to treat all Awards similarly in the transaction. 

In the event that the successor corporation does not assume or substitute for the Award consistent with subparagraph (c)(i) of this paragraph
10.3, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Share Appreciation Rights, including Common Shares as to which such Awards would not otherwise be vested or exercisable, all
restrictions on Restricted Share Awards and Restricted Share Unit Awards will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent
(100%) of target levels and all other terms and conditions met. In addition, if an Option or Share Appreciation Right is not assumed or substituted in the event of a Change of Control, the Board of Directors will notify the Participant in
writing or electronically that the Option or Share Appreciation Right will be exercisable for a period of time determined by the Board of Directors in its sole discretion, and the Option or Share Appreciation Right will terminate upon the expiration
of such period. 
 For the purposes of this subparagraph (c), an Award will be considered assumed if, following the Change of Control, the
Award confers the right to purchase or receive, for each Common Share subject to the Award immediately prior to the Change of Control, the consideration (whether stock, cash, or other securities or property) received in the Change of Control by
holders of Common Shares for each Common Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Common Shares);
provided, however, that if such consideration received in the Change of Control is not solely common shares or common stock of the successor corporation or its Parent, the Board of Directors may, with the consent of the successor corporation,
provide for the consideration to be received upon the exercise of an Option or Share Appreciation Rights or upon the payout of a Restricted Share Unit, Performance Share Award, for each Common Share subject to such Award, to be solely common shares
or common stock of the successor corporation or its parent equal in fair market value to the per share consideration received by holders of Common Shares in the Change of Control. 

Notwithstanding anything in this subparagraph (c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one
or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant’s consent; provided, 

  
 22 

 
however, a modification to such performance goals only to reflect the successor corporation’s post-Change of Control corporate structure will not be deemed to invalidate an otherwise valid
Award assumption. 
  

	 	(d)	Outside Director Awards. With respect to Awards granted to an Outside Director that are assumed or substituted for, if on the date of or following such assumption or substitution the Participant’s status as a
director of the Company or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the Participant (which does not include resignation at the request of the acquirer), then the Participant
will fully vest in and have the right to exercise Options and/or Share Appreciation Rights as to all of the Common Shares underlying such Award, including those Common Shares which would not otherwise be vested or exercisable, all restrictions on
Restricted Share Awards and Restricted Share Unit Awards will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target
levels and all other terms and conditions met. 

  

	10.4	Representations and Covenants of Award holder. Each Award Agreement will contain representations and covenants of the holder that: 

 

	 	(a)	the holder is a director, officer, employee or Consultant of the Company or of a subsidiary of the Company or a person otherwise approved as an “Eligible Person” under this Plan by the Board of Directors on
the date of grant; 

  

	 	(b)	the holder’s participation in the Plan is voluntary and the holder has not been induced to enter into such Award Agreement by the expectation of employment or engagement as a Consultant or continued employment or
engagement as a Consultant with the Company or any Affiliate; 

  

	 	(c)	the holder is aware that the grant of the Award and the issuance by the Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document (other
than a registration statement on Form S-8 with the United States Securities and Exchange Commission) qualifying the distribution of the Awards or the Common Shares to be distributed thereunder under any applicable securities laws and if such
exemption for any reason becomes unavailable, the obligation of the Company to grant any Awards or issue any Common Shares upon the exercise, vesting, or settlement of an Award, as the case may be, will cease; and 

 

	 	(d)	 the holder or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares purchased pursuant to
the exercise of the Share Awards, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchanges, and will not offer, sell or deliver
any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any company, partnership or other entity created or organized in 

  
 23 

	 	
or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the
securities laws of the United States. 

  

	10.5	Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any Stock
Exchange on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board of Directors may impose such other clawback,
recovery or recoupment provisions in an agreement evidencing the grant of the Awards as the Board of Directors determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired Common Shares.
No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any agreement with the Company or any Affiliate.

  

	10.6	Taxes 

  

	 	(a)	Withholding Requirements. Prior to the delivery of any Common Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as any tax withholding obligations are due, the Company will have the
power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy U.S. or Canadian federal, provincial, state, local, foreign or other taxes required to be withheld with respect to such
Award (or exercise thereof). 

  

	 	(b)	Withholding Arrangements. The Board of Directors, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation,
in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Common Shares having a Fair Market Value Price equal to the minimum statutory amount required to be
withheld, or (c) delivering to the Company already-owned Common Shares having a Fair Market Value Price equal to the minimum statutory amount required to be withheld. The Fair Market Value Price of the Common Shares to be withheld or delivered
will be determined as of the date that the taxes are required to be withheld. 

  

	 	(c)	 Compliance With Code Section 409A. Awards will be designed and operated in such a manner that they are either exempt from the application
of, or comply with, the requirements of Code Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A, except as otherwise determined in the
sole discretion of the Board of Directors. The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise
determined in the sole discretion of the Board of Directors. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A the 

  
 24 

	 	
Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or deferral will not be subject to
the additional tax or interest applicable under Code Section 409A. 

 ARTICLE 11 

SUSPENSION, AMENDMENT OR TERMINATION OF PLAN 
  

	11.1	The Plan will become effective upon the later to occur of (i) its adoption by the Board of Directors or (ii) the business day immediately prior to the Registration Date (the “Effective Date”). It
will continue in effect for a term of ten (10) years from the date adopted by the Board of Directors, unless terminated earlier under paragraph 11.2 of the Plan. 

 

	11.2	The Board of Directors will have the right at any time and from time to time to suspend, amend or terminate this Plan in any manner without consent or approval from Participants or shareholders (provided that no such
suspension, amendment or termination may be made that will materially prejudice the rights of any Participant under any Award previously granted to such Participant without consent by such Participant). 

 

	11.3	The full powers of the Board of Directors as provided for in this Plan will survive the termination of this Plan until all Awards have been exercised or settled in full or have otherwise expired. 

ARTICLE 12 
 APPLICABLE
LAW 
  

	12.1	The laws of the Province of British Columbia shall apply to the Plan and any Award Agreement evidencing the grant of Awards granted hereunder and will be interpreted and construed in accordance with the laws of the
Province of British Columbia. 

  

	12.2	Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with the Plan to the exclusive jurisdiction of the courts of the Province of British
Columbia. 

 ARTICLE 13 
  

	13.1	The Plan will be subject to shareholder approval within 12 months after the date the Plan is adopted by the Board. Such shareholder approval will be obtained in the manner and to the degree required under
applicable laws. 

  
 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]